STOCK TITAN

Zymeworks authorizes up to $200M buyback through 2028

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Zymeworks Inc. (ZYME) authorized a second 2026 share repurchase program under which it may repurchase up to $200.0 million of common stock through 2028. The company intends to begin repurchases before the end of 2026 and currently expects approximately $140.0 million in repurchases through 2028. It completed its initial 2026 program, which authorized up to $125.0 million. Zymeworks had approximately 68.7 million common shares outstanding as of November 11, 2026.

The company says the program will be funded through its existing balance sheet and expected near-term cash flows, including $55 million in upfront fees from a Roche collaboration closing expected before the end of 2026, pending HSR clearance, and a potential $100 million TRELEGY ELLIPTA milestone expected in the first quarter of 2027, subject to achievement of the applicable 2026 sales threshold. Repurchases may be made in open-market transactions or by other means in accordance with Rule 10b5-1 and Rule 10b-18. The program may be suspended or discontinued at any time and does not obligate the company to repurchase any amount.

Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Second 2026 repurchase authorization Up to $200.0 million Repurchases may occur through 2028
Expected repurchases Approximately $140.0 million Company expectation through 2028
Initial 2026 program authorization Up to $125.0 million Initial program described as completed
Common shares outstanding Approximately 68.7 million shares As of November 11, 2026
Roche collaboration upfront fees $55 million Expected from a closing before the end of 2026, pending HSR clearance
TRELEGY ELLIPTA milestone Potential $100 million Expected in the first quarter of 2027, subject to achievement of the applicable 2026 sales threshold
Rule 10b5-1 regulatory
"in accordance with Rule 10b5-1 of the Securities Exchange Act"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
Rule 10b-18 regulatory
"and Rule 10b-18 of the Exchange Act"
Rule 10b-18 is a regulation that sets strict rules for how a company's executives and employees can buy back their own company's stock from the market. It helps ensure that these buybacks happen in a fair and transparent way, reducing the chance of market manipulation. This is important for investors because it offers protection against unfair practices and promotes confidence in the integrity of the stock market.
HSR clearance regulatory
"pending HSR clearance"
hsr clearance is approval under the U.S. Hart-Scott-Rodino (HSR) antitrust pre‑merger notification process that allows parties to close a transaction after the required federal waiting period has ended or the agencies have expressly cleared the deal. Companies above statutory size thresholds must file HSR notifications with the Federal Trade Commission and Department of Justice and then either wait the initial statutory waiting period or respond to an agency request for additional information (a “second request”), which extends review; clearance occurs when the waiting period expires without further action or when the agencies notify the parties they will not challenge the transaction. The practical effect is that HSR clearance removes the HSR-related legal bar to consummating the acquisition or merger, though separate antitrust litigation or other regulatory approvals may still be required.
Total Shareholder Return (TSR) financial
"contributions to Total Shareholder Return (TSR)"
Total shareholder return (TSR) measures how much an investment in a company's stock has grown over a specific period by combining the change in the share price and all dividends paid, expressed as a percentage. Think of it like tracking the total balance of a savings jar that increases both from added cash (dividends) and a rising sticker price on the jar (share price); investors use TSR to compare how well different stocks or managers deliver real, money-in-hand returns.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How large is ZYME's second share repurchase authorization?

Zymeworks may repurchase up to $200.0 million of common stock through 2028. The company currently expects approximately $140.0 million in repurchases through 2028 and intends to begin the program before the end of 2026.

What cash flows are identified to fund ZYME's repurchases?

The program is to be funded through Zymeworks' existing balance sheet and expected near-term cash flows, including $55 million in Roche collaboration upfront fees from a closing expected before the end of 2026, pending HSR clearance, and a potential $100 million TRELEGY ELLIPTA milestone expected in the first quarter of 2027, subject to achievement of the applicable 2026 sales threshold.

How may ZYME conduct or stop share repurchases?

Shares may be repurchased from time to time in open-market transactions or by other means in accordance with Rule 10b5-1 and Rule 10b-18. The program may be suspended or discontinued at any time and does not obligate Zymeworks to acquire any amount of common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001937653false00019376532026-11-162026-11-16

  
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 16, 2026
Zymeworks Inc.
(Exact name of registrant as specified in its charter)
 





Delaware
001-4153588-3099146
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)


108 Patriot Drive, Suite A, Middletown, Delaware
19709
(Address of principal executive offices)(Zip Code)
(302) 274-8744
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



 



☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
 





Title of each classTrading
Symbol(s)
Name of each exchange
on which registered
Common Stock, $0.00001 par value per share
ZYME

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
 




ITEM 8.01OTHER EVENTS
On November 16, 2026, Zymeworks Inc. (the “Company”) issued a press release announcing that its Board of Directors had authorized a second 2026 share repurchase program (the “Second 2026 Share Repurchase Program”) under which the Company may repurchase up to $200.0 million of its outstanding common stock, par value $0.00001 per share, through 2028. The Company has completed its initial 2026 share repurchase program under which the Company was authorized to repurchase up to $125.0 million of its outstanding common stock.
ITEM 7.01REGULATION FD DISCLOSURE
On November 16, 2026, the Company issued a press release regarding the Second 2026 Share Repurchase Program. A copy of this press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

The information set forth in this Item 7.01 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

ITEM 9.01FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits
Exhibit No.  Description
99.1  
Press Release dated November 16, 2026.
104Cover Page Interactive Data File (embedded as Inline XBRL document)




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 

ZYMEWORKS INC.
(Registrant)
 







Date: November 16, 2026

By:/s/ Kenneth Galbraith


Name:Kenneth Galbraith


Title:Chair, President and Chief Executive Officer


image_0.jpg
Zymeworks Announces $200 Million Share Repurchase Authorization
•Zymeworks intends to commence the Share Repurchase Program with $140.0 million in share repurchases expected through 2028, with flexibility to adjust the pace of repurchases based on market opportunities, cash flow, and expected contribution to Total Shareholder Return (TSR)
•Zymeworks intends to balance capital allocation for 2027 thoughtfully across disciplined R&D pipeline development, selective M&A transactions and opportunistic share repurchases to grow underlying enterprise value while returning capital to shareholders through reducing share count over time
Vancouver, British Columbia (November 16, 2026) – Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that its Board of Directors has authorized a second 2026 share repurchase program under which the Company may repurchase up to $200.0 million of its outstanding common stock, par value $0.00001 per share.
Zymeworks completed its initial 2026 share repurchase program under which the Company was authorized to repurchase up to $125.0 million of its outstanding common stock. As of November 11, 2026, the Company had approximately 68.7 million outstanding common shares.
Zymeworks intends to commence the second 2026 Share Repurchase Program before the end of 2026, which authorizes up to $200.0 million in repurchases through 2028, demonstrating the Company’s continued commitment to returning capital to stockholders. The Company currently expects to spend approximately $140.0 million through 2028 under the program, while retaining the ability to adjust the pace of repurchases as it sees fit. The authorization provides flexibility to adapt to market conditions and opportunities to reduce share count with attractive potential contributions to long-term TSR.
“As we look ahead, our focus remains on allocating capital thoughtfully to support long-term growth and shareholder value,” said Kristin Stafford, CPA, Chief Financial Officer of Zymeworks. “Our priorities include disciplined pipeline development, selective M&A and opportunistic share repurchases, with $140.0 million in repurchases expected through 2028. Maintaining flexibility around the pace of repurchases allows us to respond to market conditions and cash flow while prioritizing opportunities to create lasting value for shareholders.”
The Share Repurchase Program will be funded through the Company’s existing balance sheet, and expected near-term cash flows of $55 million in upfront fees from the closing of the Roche collaboration expected before the end of 2026, pending HSR clearance, and the potential $100 million TRELEGY ELLIPTA® milestone payment expected in the first quarter of 2027, subject to achievement of the applicable 2026 sales threshold. The shares may be repurchased from time to time in open market transactions, or other means in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Rule 10b-18 of the Exchange Act. The timing, number of shares



repurchased, and prices paid for the shares under this program will depend on general business and market conditions as well as corporate and regulatory limitations, prevailing stock prices, and other considerations. The second 2026 share repurchase program may be suspended or discontinued at any time and does not obligate the Company to acquire any amount of common stock.
About Zymeworks Inc.

Zymeworks is a global biotechnology company building a diversified portfolio of healthcare assets designed to generate durable cash flows while advancing innovative medicines for difficult-to-treat diseases. The Company’s asset and royalty aggregation strategy combines a growing portfolio of commercial and near-commercial assets, including YUPELRI® (revefenacin), with a differentiated internal research and development engine. Zymeworks’ portfolio also includes Ziihera® (zanidatamab-hrii), a HER2-targeted bispecific antibody discovered and developed by Zymeworks and commercialized through global partnerships with Jazz Pharmaceuticals and BeOne Medicines, and pasritamig, a clinical-stage multispecific antibody developed by Johnson & Johnson using Zymeworks’ proprietary antibody engineering technologies.

Zymeworks is advancing a diverse pipeline of novel biotherapeutics, leveraging its proprietary Azymetric™ platform and expertise in antibody-drug conjugates, multispecific antibodies and other next-generation antibody technologies. These capabilities, together with Zymeworks’ integrated drug development expertise, enable the Company to develop differentiated therapeutics and create value through both internal innovation and strategic partnerships.

For more information about Zymeworks, its portfolio and pipeline, visit www.zymeworks.com and follow @ZymeworksInc on X.

Cautionary Note Regarding Forward-Looking Statements

This press release includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to Zymeworks’ ability to execute the share repurchase program, in whole or in part; HSR clearance and the closing of the agreement with Roche; achievement of the applicable 2026 sales threshold for TRELEGY ELLIPTA®; Zymeworks’ flexibility to invest in its R&D pipeline and pursue strategic opportunities while returning capital to stockholders; expected benefits to stockholders of share repurchases; Zymeworks’ expectations regarding implementation of its long-term strategy to maximize value creation; Zymeworks’ and its partners’ clinical development of product candidates; potential safety profile and therapeutic effects of product candidates; the commercial potential of technology platforms and product candidates; the anticipated benefits of its collaboration agreements; and other information that is not historical information. When used herein, words such as “plan”, “believe”, “expect”, “may”, “continue”, “anticipate”, “potential”, “will”, “on track”, “progress”, “preserve”, “intend”, “could”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain.



Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: any of Zymeworks’ or its partners’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; Zymeworks may not be able to successfully execute the share repurchase program; the anticipated benefits of the share repurchase program may not be realized; Zymeworks may not achieve milestones or receive additional payments or royalties under its collaborations; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions, including the impact of tariffs; potential negative impacts of FDA regulatory delays and uncertainty around recent policy developments, changes in the leadership of federal agencies such as the FDA, staff layoffs, budget cuts to agency programs and research, and changes in drug pricing controls; the impact of pandemics and other health crises on Zymeworks’ business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks’ behalf; zanidatamab may not be successfully commercialized; Zymeworks’ business strategy related to anticipated and potential future milestones and royalty streams and existing and potential new partnerships may not be successfully implemented; Zymeworks’ evolution of its business strategy may not deliver meaningful stockholder returns; Zymeworks may be unsuccessful in actively managing and/or aggregating revenue-generating assets alongside its active R&D operations; ongoing and future clinical trials may not demonstrate safety and efficacy of any of Zymeworks’ or its collaborators’ product candidates; data providing early validation of our antibody drug conjugate platform and next generation pipeline programs may not be replicated in future studies; Zymeworks’ assumptions and estimates regarding its financial condition, future financial performance and estimated cash runway may be incorrect; inability to maintain or enter into new partnerships or strategic collaborations; the inability of Zymeworks to identify and consummate a strategic acquisition; and the factors described under “Risk Factors” in Zymeworks’ quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at www.sec.gov and www.sedarplus.ca).

Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.

Contacts:

Investor Inquiries:
Shrinal Inamdar
Vice President, Investor Relations
(604) 678-1388
ir@zymeworks.com   

Media Inquiries:
Diana Papove



Vice President, Corporate Communications
(604) 678-1388
media@zymeworks.com

Filing Exhibits & Attachments

4 documents

Keep reading